Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jeffrey Albers Insider Profile
4 Followers
Jeffrey Albers, Director at Blueprint Medicines, holds 165.02K shares in Blueprint Medicines (Ticker: BPMC), holds 0.00 shares in Kymera Therapeutics (Ticker: KYMR), holds 4.15K shares in Dianthus Therapeutics (Ticker: DNTH). Most recently, Jeffrey Albers Sold ― shares of Blueprint Medicines on Mar 26, 2024 for an estimated value of 1.00M.
Profitable Transactions
4 out of 8 Profitable Transactions
Average Return
-26.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jeffrey Albers holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Nov 21, 2018 - Nov 21, 2019
Return:+39.50%
The most profitable trade made by Jeffrey Albers
Jeffrey Albers's Trading History
Blueprint Medicines
Mar 26, 2024
Director
Informative Sell
1.00M
$15.23M
Dianthus Therapeutics
Jun 27, 2018
Director
Uninformative Buy
―
$97.24K
Kymera Therapeutics
Feb 21, 2024
Director
Uninformative Sell
195.22K
$0.00
Spyre Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Jeffrey Albers's performance on stock
You May Also Like
Jeffrey Albers insider profile FAQ
What is the percentage of profitable transactions made by Jeffrey Albers?
The percentage of profitable transactions made by Jeffrey Albers is 50%.
What is the average return per transaction made by Jeffrey Albers?
The average return per transaction made by Jeffrey Albers is -26.30%.
What stocks does Jeffrey Albers hold?
Jeffrey Albers holds: BPMC, DNTH, KYMR, SYRE stocks.
What was Jeffrey Albers’s latest transaction?
Jeffrey Albers latest transaction was an Informative Sell of $1.00M.
What was Jeffrey Albers's most profitable transaction?
Jeffrey Albers’s most profitable transaction was an Informative Buy of BPMC stock on November 21, 2018. The return on the trade was 39.50%.
What is Jeffrey Albers's role in Blueprint Medicines?
Jeffrey Albers's role in Blueprint Medicines is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.